Art

J-GLOBAL ID：201102248417264541   Reference number：11A0492540

Bafetinib

分子標的治療薬 バフェチニブ

Author (1)： KIMURA SHIN'YA (佐賀大 医 血液・呼吸器・腫瘍内科)
Material： Biotherapy (Tokyo)  (日本バイオセラピィ学会学術集会総会プログラム・抄録集)
Volume： 25  Issue： 1  Page： 589-596  Publication year： Jan. 30, 2011 
JST Material Number： L0028A  ISSN： 0914-2223  Document type： Article
Article type： 文献レビュー  Country of issue： Japan (JPN)  Language： JAPANESE (JA)

Thesaurus term： *molecular targeting drug ,...
Semi thesaurus term： *バフェチニブ ,...

Register(free) or Log In to access     To see more with JDream III (charged).   {{ this.onShowAbsJLink("http://jdream3.com/lp/jglobal/index.html?docNo=11A0492540&from=J-GLOBAL&jstjournalNo=L0028A") }}

JST classification (1)： Basic research of antitumor(=antineoplastic)drugs  (GW16010A)

Substance index (2)： Dasatinib ,  Nilotinib

Reference (20)：

• Charles, L. and Sawyers, C. L.: Chronic myeloid leukemia. N. Engl. J. Med.340(17): 1330-1340.1999.
• O’Brien. S. G., Guilhot, F., Larson, R. A., et al.: Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N. Engl. J. Med.348(11): 994-1004, 2003.
• Yokota, A. and Kimura. S.: Novel agents to override imatinib resistance mechanisms. Drug Der. Res.69(7): 398-406, 2008.
• Kimura, S., Naito, H., Segawa, H., et al.: NS-187, a potent and selective dual Bcr-Abl/Lyn tyrosine kinase inhibitor, is a novel agent for imatinib resistant leukemia. Blood 106(12): 3948-3954, 2005.
• Asaki. T., Sugiyama, Y., Hamamoto, T., et al.: Design and synthesis of 3-substituted benza-mide derivatives as Bcr-Abl kinase inhibitors. Bioorg._ Med. Chem. Lett.16(5): 1421-1425.2006.

Terms in the title (2)： 分子標的治療薬 ,  バフェチニブ